Elevated Lipoprotein(a) (>50 mg/dL) in middle age was significantly associated with higher odds of elevated aortic valve calcium (aOR 1.82; 95% CI 1.34-2.47) and CAC in older age.
Cohort
Yes
Does elevated Lipoprotein(a) in middle age increase the risk of vascular and valvular calcification in older age?
Elevated Lipoprotein(a) in middle age is significantly associated with increased vascular and valvular calcification in older age, supporting its role in subclinical atherosclerosis.
Odds Ratio: 1.82 (95% CI 1.34–2.47)
Background Lipoprotein(a) (Lp(a)) is a potent causal risk factor for cardiovascular events and mortality. However, its relationship with subclinical atherosclerosis, as defined by arterial calcification, remains unclear. This study uses the ARIC (Atherosclerosis Risk in Communities Study) to evaluate the relationship between Lp(a) in middle age and measures of vascular and valvular calcification in older age. Methods and Results Lp(a) was measured at ARIC visit 4 (1996-1998), and coronary artery calcium (CAC), together with extracoronary calcification (including aortic valve calcium, aortic valve ring calcium, mitral valve calcification, and thoracic aortic calcification), was measured at visit 7 (2018-2019). Lp(a) was defined as elevated if >50 mg/dL and CAC/extracoronary calcification were defined as elevated if >100. Logistic and linear regression models were used to evaluate the association between Lp(a) and CAC/extracoronary calcification, with further stratification by race. The mean age of participants at visit 4 was 59.2 (SD 4.3) years, with 62.2% women. In multivariable adjusted analyses, elevated Lp(a) was associated with higher odds of elevated aortic valve calcium (adjusted odds ratio aOR, 1.82; 95% CI, 1.34-2.47), CAC (aOR, 1.40; 95% CI, 1.08-1.81), aortic valve ring calcium (aOR, 1.36; 95% CI, 1.07-1.73), mitral valve calcification (aOR, 1.37; 95% CI, 1.06-1.78), and thoracic aortic calcification (aOR, 1.36; 95% CI, 1.05-1.77). Similar results were obtained when Lp(a) and CAC/extracoronary calcification were examined on continuous logarithmic scales. There was no significant difference in the association between Lp(a) and each measure of calcification by race or sex. Conclusions Elevated Lp(a) at middle age is significantly associated with vascular and valvular calcification in older age, represented by elevated CAC, aortic valve calcium, aortic valve ring calcium, mitral valve calcification, thoracic aortic calcification. Our findings encourage assessing Lp(a) levels in individuals with increased cardiovascular disease risk, with subsequent comprehensive vascular and valvular assessment where elevated.
Obisesan et al. (Fri,) conducted a cohort in Subclinical atherosclerosis. Elevated Lipoprotein(a) (>50 mg/dL) vs. Lp(a) ≤50 mg/dL was evaluated on Elevated aortic valve calcium (>100) (aOR 1.82, 95% CI 1.34-2.47). Elevated Lipoprotein(a) (>50 mg/dL) in middle age was significantly associated with higher odds of elevated aortic valve calcium (aOR 1.82; 95% CI 1.34-2.47) and CAC in older age.